Medications for Postpartum Depression: A Guide
Key Takeaways
- Postpartum depression (PPD) is more serious than the “baby blues” and needs timely treatment.
- Screening tools like the EPDS and PHQ-9 help identify PPD but do not replace a full clinical evaluation.
- Drugs for PPD often start with SSRIs such as sertraline (Zoloft), especially when breastfeeding, due to good safety data.
- Newer medications like brexanolone (IV) and zuranolone (oral, 14-day course) provide faster symptom relief but require special monitoring and consideration of risks.
- Side effects and breastfeeding safety should be reviewed with a healthcare professional before starting or adjusting any medication.
- Supporting someone with PPD includes listening without judgment, offering practical help, encouraging professional treatment, and recognizing urgent warning signs.
- With the right mix of screening, treatment, and support, most people with PPD can recover and improve both their own well-being and their connection with their baby.
Table of Contents
What postpartum depression is—and isn’t
Postpartum depression (PPD) is a depressive episode that begins during late pregnancy or after birth. It goes beyond the short‑lived “baby blues” and can disrupt daily life, bonding, and health for both parent and infant. Postpartum psychosis is rare but an emergency that needs immediate care.
Why timely treatment matters
Evidence shows psychotherapy, medication, or both can help most people recover. The sooner treatment starts, the better the outlook.
The PP depression test: how screening works
Clinicians commonly use two brief questionnaires:
- EPDS (Edinburgh Postnatal Depression Scale): 10 items scored 0–30. Scores ≥10–13 typically prompt clinical follow‑up. The EPDS is a screening tool, not a diagnosis, and urgent action is recommended for any self‑harm response.
- PHQ‑9: A general depression screener also validated for perinatal care; it helps monitor severity and response over time.
Drugs for PPD: when medication is used
For mild symptoms, therapy alone may be enough. For moderate to severe PPD, or when therapy alone isn’t working or isn’t available soon enough, medication is often recommended. In U.S. guidelines, SSRIs are typically first‑line; SNRIs are reasonable alternatives. Choice depends on past response, side‑effect profile, and whether the parent is breastfeeding.
Breastfeeding note: Many antidepressants pass into milk at low levels, and with clinician support many parents can continue breastfeeding while treated. Decisions weigh drug benefits against potential infant exposure.
How long medicines take to work
Traditional antidepressants usually need 4–8 weeks for full effect, though sleep and appetite can improve earlier. Rapid‑acting options (below) were developed to help bridge that gap.
Freedom Starts Here. Take Back Your Life Today.
Same-Day Admissions in Austin Available.
First‑line antidepressants (SSRIs) for PPD
Zoloft and postpartum depression: what to know
Sertraline (Zoloft) is one of the most used SSRIs in the postpartum period. It’s often a first choice, especially for people who are breastfeeding, because infant serum levels are typically undetectable and reported milk transfer is very low. Clinicians still monitor infants—particularly preterm infants—for rare sedation or feeding issues. Common maternal side effects are nausea, headache, sleep changes, and sexual side effects.
Dosing and course: A typical starting dose is low and titrated up; allow several weeks to gauge benefit. Do not stop abruptly without medical guidance to reduce relapse or discontinuation symptoms. For care that addresses recovery needs unique to women—including the postpartum period—see our women‑specific addiction treatment options.
Other SSRIs and SNRIs
Escitalopram, fluoxetine, paroxetine, and citalopram are also used; SNRIs like venlafaxine or duloxetine may be options when SSRIs aren’t tolerated or effective. Selection considers prior response, comorbid anxiety, and drug interactions.
Neuroactive‑steroid treatments designed for PPD
These medicines target GABA‑A receptors and were developed based on research into the sharp postpartum drop in the neurosteroid allopregnanolone.
Brexanolone (Zulresso) — IV in a monitored setting
- What it is: The first FDA‑approved PPD drug (2019). It’s administered as a continuous IV infusion over ~60 hours in a certified facility under a REMS program because of risks of excessive sedation or loss of consciousness.
- Controlled‑substance status: Classified as Schedule IV under U.S. law.
- When used: Often considered when rapid relief is needed, when inpatient care is feasible, or when previous treatments have failed. Trials showed symptom improvement during or shortly after the infusion.
Zuranolone (Zurzuvae) — first oral PPD medication
- What it is: The first oral medication approved specifically for PPD (2023). Standard regimen is 50 mg once nightly for 14 days, taken with a fatty meal.
- Driving/impairment warning: Because of CNS‑depressant effects, do not drive or operate machinery for at least 12 hours after each dose; people may not accurately judge their own impairment.
- Breastfeeding: Zuranolone appears in low levels in human milk. Data on infant effects are limited; shared decision‑making and infant monitoring for sedation are recommended.
- How it compares: Both zuranolone and brexanolone act on GABA‑A receptors and have demonstrated clinically meaningful reductions in depression scores; practical differences include route, setting, cost/access, and safety monitoring.
Safety, side effects, and special considerations
- Common SSRI effects: Nausea, headache, sleep changes, sexual side effects. Most ease with time; clinicians adjust dose or agent as needed.
- Brexanolone: Sedation, dizziness; requires monitoring in a facility and REMS enrollment; it is a Schedule IV medicine.
- Zuranolone: Drowsiness, dizziness, diarrhea, fatigue; boxed warnings about driving impairment; take in the evening.
- Antidepressants and youth: The FDA advises close monitoring for suicidal thoughts, especially when starting or changing dose (applies to all ages, with emphasis under 25).
- Breastfeeding and meds: Many antidepressants can be compatible with breastfeeding at low infant exposure levels; coordinate with your OB‑GYN, pediatrician, or a lactation‑knowledgeable clinician. Sertraline has strong lactation safety data.
- Substance use considerations: Discuss alcohol, cannabis, sedatives, or opioid use. Combining CNS depressants with brexanolone or zuranolone can increase sedation and accident risk. Your clinician can tailor care and offer support for substance‑use concerns.
How to help someone with postpartum
Spot signs and start the conversation
Learn the symptoms (persistent sadness, anxiety, sleep/appetite changes, hopelessness, thoughts of harm). Share concerns with empathy and encourage professional care.
Offer practical support
Provide meals, household help, and time for sleep. Offer to watch the baby during naps, help with appointments, or sit in on visits if invited.
Know urgent red flags
If there’s talk of self‑harm, harm to the baby, delusions, or severe confusion, seek emergency care right away.
Nova Recovery Center Family Program — structured education and support for loved ones during treatment and early recovery.
How Nova Recovery Center Supports Addiction Recovery with Postpartum Depression
At Nova Recovery Center, we understand that drug and alcohol addiction can often be the primary diagnosis while conditions like postpartum depression appear as a secondary concern. If substance use is the primary diagnosis alongside depression, explore our comprehensive dual diagnosis treatment in Austin for integrated care. Our comprehensive treatment approach addresses both issues by focusing first on safe and structured recovery from substance use, while also recognizing and treating co-occurring mental health challenges. Through individualized treatment plans, clients receive evidence-based care that may include medical detox, residential rehab, outpatient programs, and sober living support. For mothers experiencing postpartum depression, our team provides access to mental health professionals who can integrate therapeutic approaches such as cognitive behavioral therapy and trauma-informed care. This dual-focus model ensures that while addiction recovery remains the primary goal, mental health support is never overlooked. We also emphasize building a strong support system through group therapy and family involvement, helping clients navigate both recovery and parenthood with confidence. By treating addiction and postpartum depression together, Nova Recovery Center empowers individuals to achieve long-term stability, emotional balance, and improved quality of life.
FAQs: Drugs for PPD, Zoloft, Testing & How to Help
What is the best medication for postpartum depression?
Most clinical guidance lists SSRIs (selective serotonin reuptake inhibitors) as first‑line medications for postpartum depression, chosen based on prior response, side‑effect profile, and lactation plans. Treatment is individualized and often combined with psychotherapy.
Is there a new pill for postpartum depression?
Yes. Zuranolone (brand Zurzuvae) is the first FDA‑approved oral treatment specifically for PPD; it’s typically taken nightly for 14 days and carries a driving‑impairment warning for at least 12 hours after each dose. Discuss suitability, risks, and access with a clinician.
How long do antidepressants take to work for PPD?
Antidepressants usually need several weeks to reach full effect, though sleep and appetite may improve sooner. Your clinician will monitor progress and adjust the plan as needed.
Can you take antidepressants for PPD while breastfeeding?
Many antidepressants can be used during lactation with careful monitoring. Sertraline and paroxetine are often preferred due to low infant exposure in breast milk. Decisions should be made with your healthcare provider.
Is Zoloft (sertraline) safe for postpartum depression while breastfeeding?
Authoritative reviewers consider sertraline a preferred option during breastfeeding because transfer to milk and infant serum levels are typically low. Infants should still be observed for rare sedation or feeding issues.
How long does Zoloft take to work for PPD?
Many people begin to notice benefits within 2–4 weeks, with full effect in several weeks. Ongoing follow‑up helps determine dose adjustments or alternative options.
What is a typical Zoloft dose for postpartum depression?
Dosing is individualized and titrated based on response and tolerability; clinicians often start low and adjust. Do not start, stop, or change dosing without medical guidance.
What side effects can Zoloft cause after childbirth?
Common SSRI effects include nausea, headache, sleep changes, and sexual side effects; many improve over time. Report any severe or persistent symptoms to your clinician.
Is there a test for postpartum depression?
Yes. Clinicians use validated screening tools—most commonly the Edinburgh Postnatal Depression Scale (EPDS) and sometimes the PHQ‑9—to flag risk and guide follow‑up. These are screens, not diagnoses.
What is the Edinburgh Postnatal Depression Scale (EPDS)?
The EPDS is a 10‑item questionnaire (score 0–30) designed to screen for postpartum depression and anxiety symptoms, typically used during postpartum visits. Positive screens prompt clinical evaluation.
What EPDS score suggests postpartum depression?
Cutoffs vary by setting, but scores ≥10–13 commonly trigger further assessment. Any score indicating self‑harm requires immediate attention.
Where can I take a postpartum depression test online?
Several organizations host EPDS‑based screeners; for example, Mental Health America offers a free online postpartum depression screening tool. Online screens are informational; follow up with a clinician for diagnosis and care.
How can I help someone with postpartum depression?
Offer practical help (meals, chores, baby care), listen without judgment, and encourage professional support. Sharing vetted resources and helping with appointments can reduce barriers to care.
What should partners do to support postpartum depression?
Support regular sleep, attend visits if invited, and help with daily tasks. Learn the signs of PPD and encourage evidence‑based treatment.
What should you avoid saying to someone with PPD?
Avoid minimizing language like “just snap out of it.” Instead, reflect concern, validate feelings, and focus on concrete support.
Other Drug and Alcohol Rehab Locations
Medical Disclaimer
The information on this page is intended for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Medications used for postpartum depression, including antidepressants and other prescription drugs, should only be taken under the guidance of a qualified healthcare provider. Do not start, stop, or change any medication without first consulting your doctor. If you experience severe side effects, a worsening of symptoms, or thoughts of self-harm, call 911 immediately in the United States or seek urgent medical help. For free and confidential mental health support, you can dial 988 to reach the Suicide & Crisis Lifeline, available 24/7.
Nova Recovery Center Editorial Guidelines
By instituting a policy, we create a standardized approach to how we create, verify, and distribute all content and resources we produce. An editorial policy helps us ensure that any material our writing and clinical team create, both online and in print, meets or exceeds our standards of integrity and accuracy. Our goal is to demonstrate our commitment to education and patient support by creating valuable resources within our realm of expertise, verifying them for accuracy, and providing relevant, respectful, and insightful data to our clients and families.
- U.S. Food and Drug Administration. (2024). ZURZUVAE® (zuranolone) [Prescribing information]. Center for Drug Evaluation and Research. Website: U.S. Food & Drug Administration. Retrieved October 4, 2025, from https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217369s001lbl.pdf.
- U.S. Food and Drug Administration. (2019). ZULRESSO® (brexanolone) [Prescribing information]. Center for Drug Evaluation and Research. Website: U.S. Food & Drug Administration. Retrieved October 4, 2025, from https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211371lbl.pdf.
- Drug Enforcement Administration. (2019). Schedules of controlled substances: Placement of brexanolone in Schedule IV.Federal Register. Website: federalregister.gov. Retrieved October 4, 2025, from https://www.federalregister.gov/documents/2019/06/17/2019-12721/schedules-of-controlled-substances-placement-of-brexanolone-in-schedule-iv.
- National Library of Medicine. (2025, May 15). Sertraline. In Drugs and Lactation Database (LactMed®). Website: NCBI Bookshelf. Retrieved October 4, 2025, from https://www.ncbi.nlm.nih.gov/books/NBK501191/.
- American College of Obstetricians and Gynecologists (ACOG). (2023). Treatment and management of mental health conditions during pregnancy and postpartum (Clinical Practice Guideline No. 5). Website: ACOG (PDF hosted by Project TEACH). Retrieved October 4, 2025, from https://projectteachny.org/app/uploads/2024/04/ACOG-clin-guidelines-treatment_and_management_of_mental_health.2023.pdf.
- New Jersey Chapter, American Academy of Pediatrics. (2023). Edinburgh Postnatal Depression Scale (EPDS): Scoring.Website: njaap.org. Retrieved October 4, 2025, from https://njaap.org/wp-content/uploads/2023/06/Edinburgh-Postnatal-Depression-Scale-Scoring.pdf.
- National Institute of Mental Health. (n.d.). Perinatal depression. Website: NIMH. Retrieved October 4, 2025, from https://www.nimh.nih.gov/health/publications/perinatal-depression.
